Table 2b. Clinical outcome of HNSCC patients in relation p16INK4A expression.
| Response rates | N=55 | % | p16INK4A negative | % | p16INK4A positive | % | P-value |
|---|---|---|---|---|---|---|---|
| CR | 1 | 1.8 | 1 | 2.3 | 0 | 0 | 0.614 |
| PR | 24 | 43.6 | 19 | 43.2 | 6 | 45.5 | 0.892 |
| NC | 14 | 25.5 | 11 | 25 | 3 | 27.3 | 0.877 |
| PD | 16 | 29.1 | 13 | 29.5 | 3 | 27.3 | 0.882 |
| ORR (CR+PR) | 25 | 45.5 | 20 | 45.5 | 5 | 45.5 | 1.0 |
| DCR (CR+PR+NC) | 39 | 70.9 | 31 | 70.5 | 8 | 72.7 | 0.882 |
| Survival times | N=69 | p16INK4A negative | p16INK4A positive | P-value |
|---|---|---|---|---|
| OS since diagnosis (months; interquartile range) | 30.03 (20.21–45.43) | 30.03 (20.4–45.44) | 42.97 (20.21–68.96) | 0.280 |
| OS since diagnosis HR (95% CI) | 0.688 (0.348–1.361) | 0.283 | ||
| MST from initiation of palliative treatment (months; interquartile range) | 15.38 (7.56–27) | 13.44 (6.87–25.27) | 17.64 (15.38–29.01) | 0.078 |
| MST from initiation of palliative treatment HR (95% CI) | 0.533 (0.262–1.086) | 0.083 | ||
| PFS (days) (interquartile range) | 95 (71–144) | 92 (56–156) | 97 (82–144) | 0.688 |
| PFS HR (95% CI) | 1.196 (0.495–2.888) | 0.690 | ||
| MST upon cetuximab (month; interquartile range) | 9.43 (4.53–16.39) | 9.23 (4.47–15.51) | 12.16 (5.06–24.48) | 0.162 |
| MST upon cetuximab HR (95% CI) | 0.617 (0.311–1.222) | 0.166 |
Abbreviations: CR, complete remission; HR, hazard ratio; PD, progressive disease; PR, partial remission